US20110008473A1 - Use of hypericum perforatum extracts in the treatment of neuropathic pain - Google Patents

Use of hypericum perforatum extracts in the treatment of neuropathic pain Download PDF

Info

Publication number
US20110008473A1
US20110008473A1 US12/919,360 US91936009A US2011008473A1 US 20110008473 A1 US20110008473 A1 US 20110008473A1 US 91936009 A US91936009 A US 91936009A US 2011008473 A1 US2011008473 A1 US 2011008473A1
Authority
US
United States
Prior art keywords
hypericum
pain
treatment
extract
neuropathic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/919,360
Inventor
Valentino Mercati
Franco Francesco Vincieri
Anna Rita Bilia
Carla Ghelardini
Nicoletta Galeotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aboca SpA Societa Agricola
Original Assignee
Aboca SpA Societa Agricola
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aboca SpA Societa Agricola filed Critical Aboca SpA Societa Agricola
Assigned to ABOCA S.P.A. SOCIETA AGRICOLA reassignment ABOCA S.P.A. SOCIETA AGRICOLA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BILIA, ANNA RITA, GALEOTTI, NICOLETTA, GHELARDINI, CARLA, MERCATI, VALENTINO, VINCIERI, FRANCO FRANCESCO
Publication of US20110008473A1 publication Critical patent/US20110008473A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to the use of extracts of hypericum ( Hypericum perforatum L.) flowering stems and the components thereof for the preparation of pharmaceutical preparations and/or food supplements for the treatment of various forms of neuropathic pain (caused by chemotherapy drugs, mononeuropathy or osteoarthritis).
  • hypericum Hypericum perforatum L.
  • Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.
  • Neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction in the nervous system”, which may take the form of dysaesthesia, allodynia, hyperpathy, stinging or stabbing pain.
  • Neuropathic pain is distinguished from other types of commonly reported (nociceptive) pain, including headache, backache, and other types of musculoskeletal pain, and comprises a heterogeneous group of conditions which cannot be explained by a single etiology or a particular anatomical lesion.
  • disorders of the structures of the central or peripheral nervous system include various neuropathies (diabetic neuropathy, post-herpetic neuropathy, inflammatory neuropathies, neuropathy caused by alcohol abuse and neuropathy associated with HIV/AIDS infection), and can derive from various toxins (such as neurotoxins), acute trauma (including surgical traumas), chronic trauma (such as repetitive stress syndrome), mononeuropathies, such as carpal tunnel syndrome (the most common type of mononeuropathy, which affects 2.8% to 4.6% of the adult population), and disorders of the central nervous system (such as stroke, multiple sclerosis, cerebral ischaemia, Parkinson's disease, spinal cord lesions and head injuries).
  • toxins such as neurotoxins
  • acute trauma including surgical traumas
  • chronic trauma such as repetitive stress syndrome
  • mononeuropathies such as carpal tunnel syndrome (the most common type of mononeuropathy, which affects 2.8% to 4.6% of the adult population)
  • disorders of the central nervous system such as stroke, multiple sclerosis, cerebral ischaemia, Parkinson's disease, spinal cord lesions and head injuries.
  • the disorder is not easy to diagnose, because although the nerve produces continual painful discharges, it is often anatomically intact.
  • Neuropathic pain covers a variety of pathological states and presents with a variety of symptoms, which have the following common denominators:
  • neuropathic pain affects up to 3% of the population, and that some 1 to 5% of European adults suffer from chronic pain.
  • Chronic neuropathic pain is a major problem in neurology because it is frequent and often disabling, due to its unpleasant, chronic nature.
  • the aim of pharmacological treatments should be to prevent pain, but in practice, the most that can be achieved is to reduce the pain to a bearable level.
  • Neuropathic pain therefore represents a major clinical challenge due to its severity, chronic nature, resistance to the usual treatments and serious effect on the quality of the life.
  • the main research into this disorder uses experimental metabolic, pharmacological or trauma models in rodents, which reproduce the characteristics of human pain symptoms (Ref 1-7).
  • Hypericum also known as St. John's Wort, consists of the flowering stems of Hypericum perforatum . It contains a large number of different classes of substances: naphthodianthrone derivatives such as hypericin, pseudohypericin and isohypericin, and phloroglucinol derivatives such as hyperforin. It also contains flavonoids such as hyperoside, rutin, I3,II8-biapigenin, quercetin, quercitrin and isoquercitrin, procyanidins, essential oil and xanthones.
  • naphthodianthrone derivatives such as hypericin, pseudohypericin and isohypericin
  • phloroglucinol derivatives such as hyperforin.
  • flavonoids such as hyperoside, rutin, I3,II8-biapigenin, quercetin, quercitrin and isoquercitrin, procyanidins,
  • Hypericin has been identified as “the” active ingredient, but a new component, hyperforin, which was recently identified, seems to play an important part in the efficacy of the plant, while flavonoids, in particular rutin, have been identified as compounds which can influence its activity (Ref. 8-15).
  • Freeze-dried extracts of hypericum ( Hypericum perforatum ) flowering stems and one of its components, hypericin, have proved effective in reducing the symptoms of neuropathic pain in various experimental models, following oral administration.
  • the freeze-dried extracts can derive from freeze-drying of either the whole plant material extracted with water-ethanol solvent, or of the most hydrophilic component of the plant.
  • the active doses of freeze-dried hypericum extracts range from 10 mg/kg to 100 mg/kg.
  • the freeze-dried extracts preferably derive from extraction of the whole plant with water-alcohol solvents (0-100% ethanol, methanol, isopropanol, etc.) or water-acetone solvents (0-100%) and separation and freeze-drying of a more hydrophilic component from the plant.
  • Freeze-dried hypericum extracts preferably have a content of naphthodianthrone derivatives (hypericin+pseudohypericin) amounting to not less than 0.25%, evaluated by the HPLC method (minimum 0.025 mg per kg of body weight).
  • the phloroglucinol derivatives isolated (hyperforin and adihyperforin) have proved unable to reduce neuropathic pain.
  • FIG. 1 shows the flow chart of the preparation method.
  • the freeze-dried hypericum ( Hypericum perforatum ) flowering stem extract is prepared from hypericum flowering stems. After drying and selection of the tips, extraction is performed with a water-ethanol solution containing 50-80% alcohol, with a plant:solvent ratio of 1:13.
  • the solution is concentrated under reduced pressure to remove the ethanol, and dried by a freeze-drying process in suitable freeze-dryers.
  • FIG. 2 shows the flow chart of the preparation method.
  • the freeze-dried extract of the hydrophilic fraction of hypericum was prepared by a process of physical separation of the non-hydrophilic substances, and centrifugation with a decanter. The two fractions were then freeze-dried separately.
  • the freeze-dried extract was chemically characterised by HPLC analysis, which showed a total hypericin concentration (hypericin+pseudohypericin) of 0.27 to 0.37%.
  • a reduction in the pain threshold was induced by administering oxaliplatin 2.4 mg/kg for 5 consecutive days for a total of 3 weeks. By the end of the treatment period, the pain perception threshold of the rats was statistically lower than that of the controls (Ref. 23).
  • the total freeze-dried extract at the dose of 30 and 60 mg/kg of body weight proved to be active to a statistically significant extent.
  • the freeze-dried extract of the hydrophilic fraction at the dose of 30 mg/kg of body weight proved active to a statistically significant extent in the oxaliplatin-induced neuropathy pain test.
  • Neuropathic pain is characterised by the development of an altered perception of pain, which is manifested as continuous spontaneous pain and hyperalgesia.
  • the rats were anaesthetised with chloral hydrate 400 mg/kg i.p. or sodium pentobarbital 40 mg/kg i.p..
  • the sciatic nerve was then exposed at thigh level by retracting the femoral biceps. Proximally to the trifurcation of the sciatic nerve, approx. 7 mm of nerve was released from the membranes and 4 loose ligatures were tied round the nerve, approx. 1 mm apart.
  • an identical incision was made, but without the nerve ligature (sham operation).
  • Neuropathy developed in 14 days. The tests with the potentially analgesic substances were performed on the 14th and 21st days after the operation using the paw pressure test (ref. 24).
  • the vincristine was applied (brushed) directly onto the sciatic nerve.
  • MIA monoiodoacetate

Abstract

Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.

Description

  • The present invention relates to the use of extracts of hypericum (Hypericum perforatum L.) flowering stems and the components thereof for the preparation of pharmaceutical preparations and/or food supplements for the treatment of various forms of neuropathic pain (caused by chemotherapy drugs, mononeuropathy or osteoarthritis).
    • BACKGROUND TO THE INVENTION
  • Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.
  • Within this definition a particular type of pain associated with neurological abnormalities, called neuropathic pain, is becoming increasingly important due to its significant, growing worldwide prevalence. Neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction in the nervous system”, which may take the form of dysaesthesia, allodynia, hyperpathy, stinging or stabbing pain.
  • Neuropathic pain is distinguished from other types of commonly reported (nociceptive) pain, including headache, backache, and other types of musculoskeletal pain, and comprises a heterogeneous group of conditions which cannot be explained by a single etiology or a particular anatomical lesion.
  • These disorders of the structures of the central or peripheral nervous system include various neuropathies (diabetic neuropathy, post-herpetic neuropathy, inflammatory neuropathies, neuropathy caused by alcohol abuse and neuropathy associated with HIV/AIDS infection), and can derive from various toxins (such as neurotoxins), acute trauma (including surgical traumas), chronic trauma (such as repetitive stress syndrome), mononeuropathies, such as carpal tunnel syndrome (the most common type of mononeuropathy, which affects 2.8% to 4.6% of the adult population), and disorders of the central nervous system (such as stroke, multiple sclerosis, cerebral ischaemia, Parkinson's disease, spinal cord lesions and head injuries).
  • The disorder is not easy to diagnose, because although the nerve produces continual painful discharges, it is often anatomically intact.
  • Neuropathic pain covers a variety of pathological states and presents with a variety of symptoms, which have the following common denominators:
  • pain is perceived in the absence of a permanent, identifiable tissue lesion or process;
  • unpleasant, abnormal or unusual sensations (dysaesthesia) are present, frequently described as stinging or electric shocks;
  • brief episodes of paroxystic stabbing or piercing pain are present;
  • the pain appears some time after the lesion that triggered it;
  • the pain is perceived in a region with a sensory deficit;
  • even mild stimuli are painful (allodynia);
  • marked summation and persistent activity occur after the application of repeated stimuli.
  • It is estimated that neuropathic pain affects up to 3% of the population, and that some 1 to 5% of European adults suffer from chronic pain.
  • According to the literature, in the USA the problem of neuropathic pain is potentially onerous for the national insurance systems, with a prevalence of 1.5%.
  • 80% of patients with tumours at an advanced stage present neuropathic symptoms.
  • Chronic neuropathic pain is a major problem in neurology because it is frequent and often disabling, due to its unpleasant, chronic nature.
  • It is also a type of pain which does not respond well to the most common analgesics, such as acetylsalicylic acid, paracetamol or the most common non-steroidal anti-inflammatory drugs.
  • The aim of pharmacological treatments should be to prevent pain, but in practice, the most that can be achieved is to reduce the pain to a bearable level.
  • At present, no class of drugs has proved universally effective for patients with neuropathic pain.
  • “Off-label” drugs belonging to the following categories are generally used, but cause serious side effects in the long term:
  • antidepressants
  • anticonvulsants (gabapentin)
  • opioids (methadone, oxycodone)
  • tramadol
  • lidocaine
  • cytokine-inhibiting anti-inflammatories.
  • When these drugs are effective, they reduce pain by 25-40% in 40-60% of patients.
  • Moreover, numerous adverse effects are caused by continuous use of these drugs.
  • Neuropathic pain therefore represents a major clinical challenge due to its severity, chronic nature, resistance to the usual treatments and serious effect on the quality of the life.
  • The main research into this disorder uses experimental metabolic, pharmacological or trauma models in rodents, which reproduce the characteristics of human pain symptoms (Ref 1-7).
  • Hypericum, also known as St. John's Wort, consists of the flowering stems of Hypericum perforatum. It contains a large number of different classes of substances: naphthodianthrone derivatives such as hypericin, pseudohypericin and isohypericin, and phloroglucinol derivatives such as hyperforin. It also contains flavonoids such as hyperoside, rutin, I3,II8-biapigenin, quercetin, quercitrin and isoquercitrin, procyanidins, essential oil and xanthones.
  • It is widely used in modern phytotherapy to treat some forms of mild or moderate depression and psychovegetative problems, with effective results at the dose of 500-1050 mg of extract/day divided into 2-3 doses, for 2-4 weeks, and fewer side effects than treatment with synthetic antidepressants.
  • Hypericum perforatum extracts have been tested in many experimental pharmacological and clinical trials, which fully support its use for depression, but many questions about its characteristics still remain unanswered. A number of action mechanisms have been suggested to explain its antidepressant effects: 1) non-selective serotonin, noradrenaline and dopamine reuptake inhibition; 2) increased density of the serotoninergic, dopaminergic and GABA receptors; 3) increased affinity for the GABA receptors; 4) inhibition of the enzyme monoamine oxidase (MAO). The identity of the active components is still in doubt, and its pharmacological activity seems to be complex and determined by the concomitant effects of a number of active substances. Hypericin has been identified as “the” active ingredient, but a new component, hyperforin, which was recently identified, seems to play an important part in the efficacy of the plant, while flavonoids, in particular rutin, have been identified as compounds which can influence its activity (Ref. 8-15).
  • A clinical trial (16) published in 2000 describes the inefficacy of a hypericum extract in the treatment of neuropathies.
  • Other studies describe the analgesic activity of hypericum, but they were conducted on different species from Hypericum perforatum, the extracts were not chemically characterised, the administration route was often not oral, and above all, they were evaluated on non-neuropathic pain models (hot plate test, writhing test, Ref. 16-22).
    • DESCRIPTION OF THE INVENTION
  • Freeze-dried extracts of hypericum (Hypericum perforatum) flowering stems and one of its components, hypericin, have proved effective in reducing the symptoms of neuropathic pain in various experimental models, following oral administration.
  • The studies were conducted on rodents, which have always constituted a good animal model to reproduce the characteristics of human pain symptoms and predict possible remedies.
  • The freeze-dried extracts can derive from freeze-drying of either the whole plant material extracted with water-ethanol solvent, or of the most hydrophilic component of the plant.
  • The active doses of freeze-dried hypericum extracts range from 10 mg/kg to 100 mg/kg.
  • The freeze-dried extracts preferably derive from extraction of the whole plant with water-alcohol solvents (0-100% ethanol, methanol, isopropanol, etc.) or water-acetone solvents (0-100%) and separation and freeze-drying of a more hydrophilic component from the plant.
  • Freeze-dried hypericum extracts preferably have a content of naphthodianthrone derivatives (hypericin+pseudohypericin) amounting to not less than 0.25%, evaluated by the HPLC method (minimum 0.025 mg per kg of body weight).
  • One of the naphthodianthrone derivatives, hypericin, has proved active at a dose corresponding to its concentration in freeze-dried extracts.
  • The phloroglucinol derivatives isolated (hyperforin and adihyperforin) have proved unable to reduce neuropathic pain.
  • Up to the dose of 3000 mg/kg per os the freeze-dried extract does not change the animal's behaviour, as demonstrated by the fact that the number of falls from the rotating rod consecutively declines as the sessions are repeated, demonstrating that the animals' motor coordination is wholly comparable to that of the controls (Ref. 29 Rota Rod test).
  • When analyzed in terms of numerous parameters (behaviour, movement, muscle tone, autonomic signs), the extracts did not cause any alteration. The scores of the treated animals did not differ from those of the controls (Ref. 28 Irwin test).
  • The invention is described in greater detail in the Examples and Preparations below.
  • Preparation 1. Total Freeze-Dried Extract
  • FIG. 1 shows the flow chart of the preparation method.
  • The freeze-dried hypericum (Hypericum perforatum) flowering stem extract is prepared from hypericum flowering stems. After drying and selection of the tips, extraction is performed with a water-ethanol solution containing 50-80% alcohol, with a plant:solvent ratio of 1:13.
  • The solution is concentrated under reduced pressure to remove the ethanol, and dried by a freeze-drying process in suitable freeze-dryers.
  • Preparation 2. Freeze-Dried Extract of the Hydrophilic Fraction
  • FIG. 2 shows the flow chart of the preparation method.
    •
  • The freeze-dried extract of the hydrophilic fraction of hypericum, containing polar water-soluble substances, was prepared by a process of physical separation of the non-hydrophilic substances, and centrifugation with a decanter. The two fractions were then freeze-dried separately.
  • The freeze-dried extract was chemically characterised by HPLC analysis, which showed a total hypericin concentration (hypericin+pseudohypericin) of 0.27 to 0.37%.
  • Example 1
    • Oxaliplatin-Induced Neuropathy
  • A reduction in the pain threshold was induced by administering oxaliplatin 2.4 mg/kg for 5 consecutive days for a total of 3 weeks. By the end of the treatment period, the pain perception threshold of the rats was statistically lower than that of the controls (Ref. 23).
  • The total freeze-dried extract at the dose of 30 and 60 mg/kg of body weight proved to be active to a statistically significant extent.
  • TABLE 1a
    DOSE-RESPONSE CURVE OF HYPERICUM EXTRACT ON OXALIPLATIN-
    INDUCED HYPERALGESIA IN THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT TREATMENT 3rd week + 3rd week + 3rd week +
    i.p. MG/KG P.O. Pre-test 15 min. 30 min 45 min
    SALINE CMC 57.4 ± 3.5 61.8 ± 5.4 67.4 ± 6.3 62.3 ± 5.4
    OXALIPLATIN CMC 22.6 ± 4.6 25.1 ± 6.1 26.9 ± 5.4 24.3 ± 6.6
    OXALIPLATIN HYPERICUM 21.7 ± 1.2 58.1 ± 3.5* 67.8 ± 2.0* 29.1 ± 2.0
    EXTRACT
    30 mg/kg
    OXALIPLATIN HYPERICUM 24.5 ± 1.3 48.2 ± 4.6* 25.7 ± 2.4 21.5 ± 0.0
    EXTRACT
    60 mg/kg
    Oxaliplatin 2.4 mg/kg−1 for 5 consecutive days a week (15 i.p. injections - cumulative dose 36 mg/kg)
    {circumflex over ( )}P < 0.05
    *p > 0.01
  • The freeze-dried extract of the hydrophilic fraction at the dose of 30 mg/kg of body weight proved active to a statistically significant extent in the oxaliplatin-induced neuropathy pain test.
  • TABLE 1 b
    DOSE-RESPONSE CURVE OF HYDROPHILIC FRACTION
    OF HYPERICUM EXTRACT ON OXALIPLATIN-INDUCED
    HYPERALGESIA IN THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT TREATMENT 3rd week + 3rd week + 3rd week +
    i.p. MG/KG P.O. PRE-TEST 15 min. 30 min 45 min
    SALINE CMC 57.4 ± 3.5 61.8 ± 5.4 67.4 ± 6.3 62.3 ± 5.4
    OXALIPLATIN CMC 22.6 ± 4.6 25.1 ± 6.1 26.9 ± 5.4 24.3 ± 6.6
    OXALIPLATIN HYDROPHILIC 21.0 ± 2.0 42.0 ± 1.9* 63.0 ± 1.9* 14.5 ± 1.0
    HYPERICUM
    EXTRACT
    30 mg/kg
    Oxaliplatin 2.4 mg/kg−1 for 5 consecutive days a week (15 i.p. injections - cumulative dose 36 mg/kg)
    {circumflex over ( )} P < 0.05
    *p > 0.01
    • Example 2 Mononeuropathy Induced by Ligature of the Sciatic Nerve
  • Neuropathic pain is characterised by the development of an altered perception of pain, which is manifested as continuous spontaneous pain and hyperalgesia. In this model, the rats were anaesthetised with chloral hydrate 400 mg/kg i.p. or sodium pentobarbital 40 mg/kg i.p.. The sciatic nerve was then exposed at thigh level by retracting the femoral biceps. Proximally to the trifurcation of the sciatic nerve, approx. 7 mm of nerve was released from the membranes and 4 loose ligatures were tied round the nerve, approx. 1 mm apart. In another group of animals an identical incision was made, but without the nerve ligature (sham operation). Neuropathy developed in 14 days. The tests with the potentially analgesic substances were performed on the 14th and 21st days after the operation using the paw pressure test (ref. 24).
  • The total freeze-dried extract at the dose of 10, 30, 60 and 100 mg/kg of body weight proved to be active to a statistically significant extent.
  • TABLE 2a
    EFFECT OF HYPERICUM EXTRACT IN A RIGHT-SIDE MONONEUROPATHY
    MODEL IN RATS, EVALUATED WITH THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT Before After treatment
    i.p. PAW treatment 15 min 30 min 45 min
    CMC L 60.5 ± 3.8 61.8 ± 3.7 64.6 ± 3.3 59.8 ± 3.2
    CMC R 22.8 ± 2.2 21.6 ± 3.5 23.0 ± 2.6 21.9 ± 3.7
    HYPERICUM L 56.2 ± 6.6 56.2 ± 7.2 58.7 ± 3.9 51.2 ± 4.3
    EXTRACT R 20.9 ± 4.0 22.5 ± 3.2 33.7 ± 4.7 {circumflex over ( )} 18.7 ± 2.4
    10 mg/kg
    HYPERICUM L 63.3 ± 5.7 68.8 ± 4.4 73.3 ± 6.7 51.7 ± 7.5
    EXTRACT R 20.3 ± 4.4 59.8 ± 3.1 * 65.5 ± 1.7 * 31.3 ± 1.7
    30 mg/kg
    HYPERICUM L 62.6 ± 3.0 68.5 ± 4.1 77.6 ± 4.3 60.7 ± 2.2
    EXTRACT R 21.9 ± 2.4 37.0 ± 2.8 {circumflex over ( )} 41.8 ± 4.4 * 22.7 ± 2.4
    60 mg/kg
    HYPERICUM L 62.8 ± 1.7 72.2 ± 2.4 78.6 ± 2.0 62.5 ± 3.8
    EXTRACT R 21.3 ± 2.7 27.5 ± 4.3 31.5 ± 4.3 * 20.5 ± 2.9
    100 mg/kg
    {circumflex over ( )} P < 0.05
    * p > 0.01
  • The freeze-dried extract of the hydrophilic fraction at the doses of 10, 30, 60 and 100 mg/kg of body weight proved active to a statistically significant extent, as shown in Table 2b below.
  • TABLE 2 b
    EFFECT OF HYDROPHILIC FRACTION OF HYPERICUM
    EXTRACT IN A RIGHT-SIDE MONONEUROPATHY MODEL IN
    RATS, EVALUATED WITH THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT BEFORE AFTER TREATMENT
    MG/KG P.O. PAW TREATMENT 15 min 30 min 45 min
    CMC L 60.5 ± 3.8 61.8 ± 3.7 64.6 ± 3.3 59.8 ± 3.2
    CMC R 22.8 ± 2.2 21.6 ± 3.5 23.0 ± 2.6 21.9 ± 3.7
    HYDROPHILIC L 60.9 ± 4.7 62.5 ± 5.8 61.3 ± 6.0 58.2 ± 3.0
    HYPERICUM R 20.3 ± 2.9 33.5 ± 3.3 41.6 ± 3.5 * 19.8 ± 6.0
    EXTRACT
    10 mg/kg
    HYDROPHILIC L 59.4 ± 4.6 67.5 ± 4.8 63.6 ± 2.4 58.7 ± 3.1
    HYPERICUM R 22.3 ± 2.4 55.1 ± 3.2 * 62.0 ± 3.5 * 26.5 ± 3.3
    EXTRACT
    30 mg/kg
    HYDROPHILIC L 60.4 ± 3.6 65.8 ± 2.0 71.2 ± 3.7 57.7 ± 4.8
    HYPERICUM R 20.2 ± 2.3 52.4 ± 3.7 * 59.7 ± 3.0 * 24.5 ± 3.2
    EXTRACT
    60 mg/kg
    HYDROPHILIC L 63.7 ± 3.5 71.2 ± 4.3 73.0 ± 2.9 61.2 ± 3.1
    HYPERICUM R 23.5 ± 3.9 30.2 ± 3.4 35.8 ± 2.5 * 20.3 ± 3.3
    EXTRACT
    100 mg/kg
    {circumflex over ( )} P < 0.05
    * p > 0.01
    • Example 3 Paclitaxel-Induced Neuropathy
  • The total freeze-dried extract at the doses of 30 and 100 mg/kg of body weight and the extract of the hydrophilic fraction at the dose of 30 mg/kg proved active to a statistically significant extent in the paclitaxel-induced neuropathic pain test (Ref. 25).
  • TABLE 3
    EFFECT OF HYPERICUM EXTRACT (30 and 100
    mg/kg−1 p.o.) AND THE HYDROPHILIC FRACTION ON
    PACLITAXEL-INDUCED HYPERALGESIA IN THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT TREATMENT Before treatment
    i.p. p.o. Pre-test 75 min 30 min 45 min
    SALINE SALINE 57.2 ± 3.9 62.6 ± 4.4 58.3 ± 4.7 56.9 ± 3.9
    PACLITAXEL SALINE 43.7 ± 4.2 39.6 ± 3.8 41.9 ± 4.3 42.5 ± 4.9
    SALINE HYPERICUM 62.6 ± 3.3 59.8 ± 4.4 57.6 ± 4.7 60.1 ± 4.6
    EXTRACT
    30 mg/kg
    BATCH 7I0525
    PACLITAXEL HYPERICUM 40.5 ± 3.8 50.3 ± 3.4 * 48.0 ± 4.0 36.6 ± 4.2
    EXTRACT
    30 mg/kg
    BATCH 7I0525
    PACLITAXEL HYPERICUM 39.6 ± 3.3 51.6 ± 3.1 * 46.3 ± 3.9 39.5 ± 4.0
    EXTRACT
    100 mg/kg
    BATCH 7I0525
    PACLITAXEL HYDROPHILIC 38.3 ± 3.9 49.2 ± 3.8 * 44.0 ± 3.5 33.8 ± 3.7
    FRACTION
    30 mg/kg
    BATCH 7I0660
    Treatment: Paclitaxel 0.5 mg/kg−1 was injected i.p. for four days (days 1, 3, 5 and 8). The cumulative dose of Paclitaxel was 2.0 mg/kg−1. The test was performed 14-15 days after the last injection of paclitaxel. Vehicle: Saline: ethylene oxide 9:1 8 rats per group (two experiments).
    {circumflex over ( )} P < 0.05; versus rats treated with paclitaxel.
    • Example 4 Vincristine-Induced Hyperalgesia
  • A reduction in the pain threshold was obtained in the rat by i.v. administration of vincristine (150 gamma/kg i.v. every 2 days for 5 days until the cumulative dose of 750 gamma/kg was reached); the test (paw-pressure) was conducted 4 days after the last injection (Ref. 26).
  • Alternatively, the vincristine was applied (brushed) directly onto the sciatic nerve. The total freeze-dried extract at the doses of 30 and 100 mg/kg of body weight and the freeze-dried extract of the hydrophilic fraction at the dose of 30 mg/kg proved active to a statistically significant extent.
  • TABLE 4
    EFFECT OF HYPERICUM EXTRACT (30 and 100 mg kg−1 p.o.)
    AND THE HYDROPHILIC FRACTION ON VINCRISTINE-INDUCED
    HYPERALGESIA IN THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    TREATMENT TREATMENT Before treatment
    mg kg−1 i.v. mg kg−1 p.o. Pre-test 15 min 30 min 45 min 60 min
    SALINE SALINE 61.6 ± 3.3 57.2 ± 4.5 62.4 ± 4.0 58.3 ± 4.1 61.6 ± 5.3
    VINCRISTINE SALINE 35.2 ± 3.4 33.8 ± 4.5 35.1 ± 3.6 36.2 ± 3.7 34.9 ± 2.8
    SALINE HYPERICUM 56.3 ± 3.3 63.4 ± 4.0 61.6 ± 3.8 57.3 ± 4.4 58.7 ± 3.3
    EXTRACT
    30 mg/kg
    BATCH 7I0525
    VINCRISTINE HYPERICUM 34.9 ± 3.1 52.6 ± 4.2* 51.9 ± 4.5* 38.3 ± 5.0 34.9 ± 5.2
    EXTRACT
    30 mg/kg
    BATCH 7I0525
    VINCRISTINE HYPERICUM 33.90 ± 3.5 48.2 ± 4.1* 47.5 ± 4.7* 35.7 ± 4.1
    EXTRACT
    100 mg/kg
    BATCH 7I0525
    VINCRISTINE HYPERICUM 31.5 ± 3.2 50.9 ± 3.7* 53.4 ± 4.2* 36.5 ± 4.9 31.3 ± 3.8
    EXTRACT
    30 mg/kg
    BATCH 7I0660
    Treatment with vincristine: five i.v. injections of 150 μg/kg−1 performed every 2 days up to a cumulative dose of 750 μg/kg−1 i.v. The test was performed 4 days after the last injection of vincristine. 7-8 rats per group (two experiments).
    {circumflex over ( )}P < 0.05
    *P < 0.01 versus rats treated with vincristine 14 rats per group (two experiments).
    *P < 0.05 versus rats treated with vincristine.
    • Example 5 Hypericin in Oxaliplatin-Induced Neuropathy
  • Using the same method as in Example 1, the following results were obtained by administering hypericin at the doses indicated in Table 5.
  • TABLE 5
    EFFECT OF HYPERICIN (single administration) ON OXALIPLATIN-
    INDUCED HYPERALGESIA IN THE RAT PAW PRESSURE TEST
    Pressure on rats' paws (g)
    Treatment period (weeks of oxaliplatin)
    Pre-test
    TREATMENT TREATMENT before all 3rd week 3rd week + 3rd week + 3rd week + 3rd week +
    i.p. p.o. treatments Pre-test 15 min 30 min 45 min 60 min
    SALINE SALINE 60.1 ± 2.2 66.2 ± 4.5 65.0 ± 4.3 63.9 ± 3.8 66.5 ± 4.4 68.1 ± 4.1
    OXALIPLATIN SALINE 58.4 ± 4.6 30.5 ± 4.7 28.4 ± 4.1 25.8 ± 3.6 27.1 ± 4.1 29.1 ± 2.8
    OXALIPLATTN HYPERICIN 63.2 ± 3.5 32.4 ± 2.0 44.1 ± 2.8* 55.0 ± 2.2* 53.3 ± 2.6* 31.3 ± 3.0
    0.11 mg/kg +
    CMC
    OXALIPLATIN HYPERICIN 60.6 ± 3.8 31.7 ± 2.5 56.3 ± 2.6* 58.5 ± 2.7* 52.5 ± 1.2* 33.0 ± 2.8
    0.11 mg/kg +
    HYPERISIDE
    3.118 mg/kg
    Treatment: Oxaliplatin 2.4 mg kg−1 for 5 consecutive days a week (15 i.p. injections - cumulative dose 36 mg/kg)
    8 rats per group (two experiments).
    *P < 0.01
    • Example 6 Hypericin in Neuropathy Induced by Ligature of the Sciatic Nerve
  • Using the same method as in Example 2, the following results were obtained by administering hypericin at the doses indicated in Table 6.
  • TABLE 6
    EFFECT OF HYPERICIN IN A RIGHT-SIDE MONONEUROPATHY MODEL
    IN THE RAT, EVALUATED WITH THE RAT PAW PRESSURE TEST
    Paw
    TREATMENT Before After treatment
    MG/KG. P.O. PAW treatment 15 min 30 min 4 min 60 min
    CMC L 60.8 ± 2.9 57.8 ± 3.3 57.4 ± 3.8 59.2 ± 4.9 55.9 ± 3.8
    CMC R 23.2 ± 2.2 24.7 ± 3.5 22.9 ± 2.8 23.6 ± 3.7 20.7 ± 3.5
    HYPERICIN L 21.6 ± 2.7 23.8 ± 3.3 22.7 ± 2.1 24.8 ± 3.9 21.5 ± 3.0
    0.11 mg/kg
    HYPERICIN R 24.3 ± 4.6 28.1 ± 1.2 43.7 ± 2.0* 41.6 ± 2.7* 25.9 ± 2.2
    0.11 mg/kg
    The doses of hypericin, hyperoside and amentoflavone corresponded to 30 mg/kg p.o. of hydrophilic fraction of hypericum extract - batch 070305/I)
    {circumflex over ( )}P < 0.05;
    *P < 0.01. Each value represents the mean of 8 rats.
    • Example 7 Effect of Freeze-Dried Hypericum Extract and Hypericin in Pain Caused by Monosodium Iodoacetate-Induced Osteoarthritis
  • The reduction in the pain threshold was induced by a single administration of monoiodoacetate (MIA) into the paw joint of the rat (Ref. 27).
  • TABLE 7
    EFFECT OF HYPERICIN AND HYPERICUM EXTRACT
    ON PAIN INDUCED BY OSTEOARTHRITIS OF THE KNEE,
    EVALUATED IN THE RAT PAW PRESSURE TEST
    TREAT- TREATMENT After treatment
    MENT mg kg−1 p.o. Pre-test 15 min 30 min 45 min 60 min
    SALINE CMC 63.9 ± 3.3 64.6 ± 2.5 60.5 ± 3.8 62.6 ± 3.7 64.6 ± 4.0
    MIA CMC 22.6 ± 2.9 20.3 ± 4.1 24.9 ± 2.7 23.2 ± 3.5 24.0 ± 2.7
    MIA HYPERICIN 23.4 ± 3.3 45.9 ± 2.7* 49.7 ± 3.8* 42.8 ± 3.9* 31.7 ± 3.5
    0.11 mg/kg
    MIA HYPERICUM 21.1 ± 2.1 39.7 ± 3.1* 42.7 ± 2.1* 38.4 ± 3.3* 22.1 ± 3.0
    EXTRACT
    60 mg/kg
    BATCH 7I0525
    Treatment: Monosodium iodoacetate (MIA) 2 mg in a volume of 25 μl was injected into the antechamber of the left knee of non-anaesthetised rats. Each value represents the mean of 2 experiments (11 rats).
    {circumflex over ( )}P < 0.05
    *P < 0.01 by comparison with rats treated with MIA/CMC.
    Fernihough J. et al. Pain 112: 83-93 (2004).
    • REFERENCES
  • 1. Nanna B et al “An evidence-based algorithm for the treatment of neuropathic pain” Medscape General Medicine 2007; 9(2):36.
  • 2. Bridges D, Thompson S W, Rice A S. Mechanisms of neuropathic pain. Br J Anaesth. 2001; 87(1):12-26. Review.
  • 3. Andres J. D.; Garcia-Ribas G. Neuropathic Pain Treatment: The Challenge Pain Practice; 2003, 3, (1): 1-7.
  • 4. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain. 2004 Nov; 112(1-2): 83-93.
  • 5. Jackson K C 2nd. Pharmacotherapy for neuropathic pain. Pain Pract. 2006 Mar; 6(1): 27-33.
  • 6. Dworkin R H, Backonja M, Rowbotham M C, Allen R R, Argoff C R, Bennett G J, Bushnell M C, Farrar J T, Galer B S, Haythornthwaite J A, Hewitt D J, Loeser J D, Max M B, Saltarelli M, Schmader K E, Stein C, Thompson D, Turk D C, Wallace M S, Watkins L R, Weinstein S M. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60(11): 1524-34.
  • 7. Taylor R S. Epidemiology of refractory neuropathic pain. Pain Pract. 2006 Mar; 6(1): 22-6.
  • 8. Butterweck V. Mechanism of action of St John's wort in depression: what is known? CNS Drugs. 2003; 17(8): 539-62.
  • 9. Rodriguez-Landa J F, Contreras C M. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine. 2003 Nov; 10(8): 688-99.
  • 10. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci. 2004 Jul 16; 75(9): 1021-7.
  • 11. No authors listed] Monograph. Hypericum perforatum. Altern Med Rev. 2004 Sep; 9(3): 318-25.
  • 12. Di Carlo G, Borrelli F, Ernst E, Izzo A A. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci. 2001 Jun; 22(6): 292-7.
  • 13. Müller WE. Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res. 2003 Feb; 47(2): 101-9.
  • 14. Nöldner M, Schötz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med. 2002 Jul; 68(7): 577-80.
  • 15. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci. 2003 Jun 20; 73(5): 627-39.
  • 16. Sindrup S H, Madsen C, Bach F W, Gram L F, Jensen T S. St. John's wort has no effect on pain in polyneuropathy. Pain. 2001 Apr; 91(3): 361-5.
  • 17. Sánchez-Mateo C C, Bonkanka CX, Hernández-Pérez M, Rabanal R M. Evaluation of the analgesic and topical anti-inflammatory effects of Hypericum reflexum L. fil. J Ethnopharmacol. 2006; 11; 107(1): 1-6.
  • 18. Trovato A, Raneri E, Kouladis M, Tzakou 0, Taviano MF, Galati E M. Anti-inflammatory and analgesic activity of Hypericum empetrifolium Willd. (Guttiferae). Farmaco. 2001; 56(5-7): 455-7.
  • 19. Viana A F, Heckler A P, Fenner R, Rates S M. Antinociceptive activity of Hypericum caprifoliatum and Hypericum polyanthemum (Guttiferae). Braz J Med Biol Res. 2003; 36(5): 631-4.
  • 20. Rabanal R M, Bonkanka C X, Hernández-Párez M, Sánchez-Mateo CC. Analgesic and topical anti-inflammatory activity of Hypericum canariense L. and Hypericum glandulosum Ait. J Ethnopharmacol. 2005 Jan 15; 96(3): 591-6.
  • 21. Bukhari I A, Dar A, Khan R A. Antinociceptive activity of methanolic extracts of St. John's Wort (Hypericum perforatum) preparation. Pak J Pharm Sci. 2004; 17(2): 13-9.
  • 22. Abdel-Salam OM Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. ScientificWorldJournal. 2005 Aug 8; 5: 586-95.
  • 23. Cavaletti G, Tredici G, Petruccioli M G, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne G G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001; 37(18): 2457-63.
  • 24. Bennett G J, Xie Y K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988; 33(1): 87-107.
  • 25. Polomano R C, Mannes A J, Clark U S, Bennett G J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001 Dec; 94(3): 293-304.
  • 26. Aley K O, Reichling D B, Levine J D. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996 Jul; 73(1): 259-65.
  • 27. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain. 2004 Nov; 112(1-2): 83-93.
  • 28. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968 Sep 20; 13(3): 222-57.
  • 29. Vaught J L, Pelley K, Costa L G, Setler P, Enna S J. A comparison of the antinociceptive responses to the GABA-receptor agonists THIP and baclofen. Neuropharmacology. 1985 Mar; 24(3): 211-6.

Claims (8)

1. The use of hypericum (Hypericum perforatum L.) flowering stems extracts containing hypericin, or hypericin, for the preparation of medicaments and/or food supplements for the treatment of neuropathic pain.
2. The use as claimed in claim 1, wherein the neuropathic pain is caused by treatment with chemotherapy drugs.
3. The use as claimed in claim 2, wherein the chemotherapy drugs are platinum complexes, vincristine and paclitaxel.
4. The use as claimed in claim 1, wherein the neuropathic pain derives from sciatic pain.
5. The use as claimed in claim 1, wherein the neuropathic pain derives from osteoarthritis.
6. The use as claimed in claim 1 of hypericum extracts with a naphthodianthrone derivative (hypericin and pseudohypericin) content of not less than 0.25%.
7. The use of a freeze-dried extract as claimed in claim 1.
8. The use as claimed in claim 7, wherein the extract is a water-alcohol or water-acetone extract.
US12/919,360 2008-02-27 2009-02-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain Abandoned US20110008473A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2008A00316 2008-02-27
IT000316A ITMI20080316A1 (en) 2008-02-27 2008-02-27 USE OF HYPERICUM PERFORATUM EXTRACTS IN THE TREATMENT OF NEUROPATHIC PAIN
PCT/EP2009/001211 WO2009106263A1 (en) 2008-02-27 2009-02-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/001211 A-371-Of-International WO2009106263A1 (en) 2008-02-27 2009-02-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/111,386 Division US8906430B2 (en) 2008-02-27 2011-05-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
US20110008473A1 true US20110008473A1 (en) 2011-01-13

Family

ID=40291708

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/919,360 Abandoned US20110008473A1 (en) 2008-02-27 2009-02-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain
US13/111,386 Active 2030-03-04 US8906430B2 (en) 2008-02-27 2011-05-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/111,386 Active 2030-03-04 US8906430B2 (en) 2008-02-27 2011-05-19 Use of hypericum perforatum extracts in the treatment of neuropathic pain

Country Status (8)

Country Link
US (2) US20110008473A1 (en)
EP (1) EP2247296B1 (en)
DK (1) DK2247296T3 (en)
ES (1) ES2588025T3 (en)
IT (1) ITMI20080316A1 (en)
PL (1) PL2247296T3 (en)
PT (1) PT2247296T (en)
WO (1) WO2009106263A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120335A1 (en) * 2012-07-13 2014-01-14 Aboca Spa Societa Agricola NEW COMPOSITIONS FOR NEUROPATHIC PAIN TREATMENT.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197823B1 (en) * 1999-09-29 2001-03-06 Medical Merchandising, Inc. Pain reliever and method of use
US20030207940A1 (en) * 1999-07-09 2003-11-06 Jacqueline J. Shan Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2077884C1 (en) * 1993-02-18 1997-04-27 Игорь Электринович Острейковский Method of patient treatment with central nervous system damage
IT1301678B1 (en) * 1998-06-10 2000-07-07 Indena Spa HYPERICUM PERFORATUM EXTRACTS AND FORMULATIONS CONTAINING THEM.
CN1076618C (en) * 1999-07-30 2001-12-26 黄斌章 Liquid medicine for treating wound and pain
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207940A1 (en) * 1999-07-09 2003-11-06 Jacqueline J. Shan Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics
US6197823B1 (en) * 1999-09-29 2001-03-06 Medical Merchandising, Inc. Pain reliever and method of use

Also Published As

Publication number Publication date
PT2247296T (en) 2016-08-23
ES2588025T3 (en) 2016-10-28
EP2247296A1 (en) 2010-11-10
EP2247296B1 (en) 2016-06-01
WO2009106263A1 (en) 2009-09-03
PL2247296T3 (en) 2016-12-30
US20110218249A1 (en) 2011-09-08
DK2247296T3 (en) 2016-09-05
ITMI20080316A1 (en) 2009-08-28
US8906430B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
El-Seedi et al. Honeybee products: An updated review of neurological actions
Hunt et al. Effect of St. John's wort on free radical production
Talaei et al. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial
Mathew et al. Bacopa monnieri and Bacoside-A for ameliorating epilepsy associated behavioral deficits
Matthys et al. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study
Yuan et al. The protective effects of Achyranthes bidentata polypeptides in an experimental model of mouse sciatic nerve crush injury
Onaolapo et al. Brain ageing, cognition and diet: a review of the emerging roles of food-based nootropics in mitigating age-related memory decline
González-Trujano et al. Justicia spicigera Schltdl. and kaempferitrin as potential anticonvulsant natural products
Mannelli et al. Widespread pain reliever profile of a flower extract of Tanacetum parthenium
Shohag et al. Perspectives on the molecular mediators of oxidative stress and antioxidant strategies in the context of neuroprotection and neurolongevity: an extensive review
Mohtashami et al. Neuroprotective natural products against experimental autoimmune encephalomyelitis: A review
KR101141439B1 (en) Composition comprising the extract of Zingiberis Rhizoma Crudus or Zingiberis Siccatum Rhizoma for prevention and treatment of memory and cognitive impairments involved disorders
US8906430B2 (en) Use of hypericum perforatum extracts in the treatment of neuropathic pain
DE10350194B4 (en) Use of extracts from Opuntia for the treatment of depressive moods and disorders
DE112006002340T5 (en) Medicines used to treat prostate cancer
Kan et al. Effect of Sustained Systemic Administration of Ginger (Z officinale) Rhizome Extracts on Salivary Flow in Mice
EP2043668B1 (en) Use of echinacea or preparations thereof in compositions for the treatment of anxiety
Timothy et al. Anticonvulsant screening of the aqueous and ethanol extracts of Mitragyna inermis bark in pentylenetetrazole and strychnine induced seizures in Albino rats
KR101029699B1 (en) The composition for the improvements and prevention of the symptoms in the alzheimer&#39;s disease comprising the extracts from oriental herb medicines
Dubiwak et al. Amelioration of nephrotoxicity in mice induced by antituberculosis drugs using Ensete ventricosum (Welw.) Cheesman corm extract
US20180133275A1 (en) Use of botanical extracts for improving brain health through enhanced neurogenesis
Gul et al. Neuropharmacological screening of Ficus Carica Linn; Fruit for Anxiolytic and Antidepressant Activity
DE102013202368A1 (en) Use of extracts from calendula for the treatment and prevention of disorders and impairments of cognitive and mental functions
Hussein et al. ORIGANUM MAJORANA ATTENUATES CIPROFLOXACIN-INDUCED NEPHROPATHY IN RATS
Prajapati et al. Evaluation of Anti-Psychotic potential of Phytocompound rich Fractions of Methanolic extract of Lagenaria siceraria (Bottle Gourd) fruits in Murine Models of Schizophrenia

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABOCA S.P.A. SOCIETA AGRICOLA, ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MERCATI, VALENTINO;VINCIERI, FRANCO FRANCESCO;BILIA, ANNA RITA;AND OTHERS;REEL/FRAME:024986/0307

Effective date: 20100830

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION